Cancer Center Support Grant

Cancer Center Support Grant
Name	Cancer Center Support Grant
Established	1970s
Administered by	National Cancer Institute
Country	United States
Purpose	Support for cancer research centers

Contents

Cancer Center Support Grant

The Cancer Center Support Grant is a major funding mechanism administered to designated cancer research centers to support infrastructure, research programs, clinical trials, and training. The mechanism is central to the National Cancer Institute's strategy for coordinating translational oncology, cooperative groups, and population studies across institutions such as Johns Hopkins Hospital, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Fred Hutchinson Cancer Center. Recipients interact with networks including the National Institutes of Health, Clinical Trials Network, Cancer Moonshot, American Cancer Society, and regional consortia.

Overview

The Cancer Center Support Grant provides core funding to centers that integrate basic, translational, clinical, and population sciences; examples of participating entities include Columbia University Irving Medical Center, Yale Cancer Center, UCLA Jonsson Comprehensive Cancer Center, University of Chicago Medicine, and University of Michigan Comprehensive Cancer Center. The mechanism supports shared resources such as biostatistics cores, molecular pathology cores, and clinical trials offices, enabling collaboration with organizations like Food and Drug Administration, Biotechnology Industry Organization, American Association for Cancer Research, Society for Immunotherapy of Cancer, and Association of American Medical Colleges. It underpins participation in initiatives led by Department of Health and Human Services, National Institutes of Health Clinical Center, and consortia including Stand Up To Cancer, NCI Community Oncology Research Program, and All of Us Research Program.

The grant evolved from early federal investments in cancer research linked to legislation and programs involving President Richard Nixon's initiatives, National Cancer Act of 1971, and subsequent National Cancer Institute reorganizations. Early sites included institutions such as Harvard University, University of Pennsylvania, Massachusetts General Hospital, Washington University in St. Louis, and Stanford University School of Medicine. Over decades, the program adapted to advances highlighted by landmark trials at Mayo Clinic, discoveries at Cold Spring Harbor Laboratory, and policy shifts influenced by panels convened at Institute of Medicine and reports from National Academies of Sciences, Engineering, and Medicine. The grant's scope expanded with precision oncology movements driven by findings at Broad Institute, Salk Institute, and MD Anderson Cancer Center.

Eligible applicants are typically academic medical centers, freestanding cancer hospitals, or consortia such as City of Hope, Cleveland Clinic, Vanderbilt University Medical Center, University of Texas Southwestern Medical Center, and Northwestern University. Applicants submit proposals through channels aligned with National Institutes of Health procedures and must document integrated programs, leadership teams, and community outreach comparable to activities at University of California San Francisco, Duke University School of Medicine, Emory University School of Medicine, Icahn School of Medicine at Mount Sinai, and Rush University Medical Center. Review panels include subject experts from American Society of Clinical Oncology, representatives from National Cancer Institute, and external reviewers linked to institutions like Fred Hutchinson Cancer Research Center. Successful applicants commonly demonstrate collaborations with regional partners such as Georgetown University Medical Center, St. Jude Children's Research Hospital, Oregon Health & Science University, University of Colorado Anschutz Medical Campus, and Rutgers University.

Funding levels are determined by peer review and programmatic priorities set by bodies including National Cancer Institute Director offices, oversight from Department of Health and Human Services, and advisory boards resembling those at National Institutes of Health Clinical Center. Grants fund cores in genomics, proteomics, imaging, and biostatistics, supporting collaborations with laboratories at Salk Institute for Biological Studies, Broad Institute of MIT and Harvard, and Whitehead Institute. Administrative components require coordination of compliance with agencies such as Food and Drug Administration, contracting with industry partners like Pfizer, Roche, and Merck, and partnerships with foundations such as Komen Foundation and Walton Family Foundation. Financial oversight involves university offices of sponsored programs at institutions like Cornell University, Brown University, and Princeton University.

The grant has enabled landmark translational studies at centers including Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, MD Anderson Cancer Center, Stanford Cancer Institute, and University of Pennsylvania Perelman School of Medicine leading to FDA approvals and clinical guidelines from groups such as National Comprehensive Cancer Network and American Society of Clinical Oncology. It has supported trials in immunotherapy influenced by findings at Parker Institute for Cancer Immunotherapy, genome-driven oncology programs at Broad Institute, and population studies collaborating with Centers for Disease Control and Prevention and Surveillance, Epidemiology, and End Results Program. Training supported trainees who have become leaders at NCI Cancer Centers, editorial roles at journals like Journal of Clinical Oncology and Cancer Cell, and investigators at biotechnology firms such as Genentech and Illumina.

Critiques have focused on concentration of funds among elite centers such as Johns Hopkins Hospital and Memorial Sloan Kettering Cancer Center, debates over allocation fairness involving NCI Community Oncology Research Program participants, and tensions between academic priorities and pharmaceutical collaborations with firms like Novartis and AstraZeneca. Controversies include conflicts of interest reviews prompted by cases linked to investigators at institutions like Harvard Medical School and discussions about geographic disparities affecting centers in states represented by Texas Medical Center and rural partners such as University of New Mexico Health Sciences Center. Policy debates have been shaped by testimony before committees of United States Congress and reports from Government Accountability Office and Office of Inspector General.

Category:Cancer research funding